LPKF

(CDAX, Industrial Goods & Services, LPK GR)

WARBURG RESEARCH

Buy	
EUR 10.00	(EUR 10.30)
Price	EUR 6.96
Upside	**43.7 %**

Value Indicators:	EUR
DCF:	10.01
FCF-Value Potential 27e:	9.70

Warburg Risk Score:	**2.5**
Balance Sheet Score:	4.0
Market Liquidity Score:	1.0

Description:

Highly specialised machine manufacturer developing laser applications for special purposes

Market Snapshot:	EUR m
Market cap:	170.5
No. of shares (m):	24.5
EV:	171.4
Freefloat MC:	170.5
Ø Trad. Vol. (30d):	219.55 th

Shareholders:	
Freefloat	100.00 %
Small Cap World Fund	*5.00 %*
JPMorgan AM	*3.00 %*
Société Générale	*3.00 %*
UBS	*3.00 %*

Key Figures (WRe):	2025e
Beta:	1.3
Price / Book:	1.9 x
Equity Ratio:	68 %
Net Fin. Debt / EBITDA:	0.1 x
Net Debt / EBITDA:	0.1 x

Profit warning announced together with new efficiency programme

LPKF revised its 2025 guidance on Monday and announced the initiation of an efficiency programme. It is striking that the share price came under pressure last Thursday, shortly before the announcement.

2025 revenues are now expected in a range of EUR 115 – 125m, down from EUR 125 – 140m. This follows weak Q2 order intake and a book-to-bill ratio of only 0.7x, which was negatively impacted by the US tariffs. This is likely to have been the main culprit behind the reduced outlook as customers hesitate to make investment decisions (especially in Europe) or relocate their production chains (mostly Asia). Demand from US customers is largely panning out as planned. The adj. EBIT margin is now seen in a range of 0-5%, down from 6-9%, which reflects the lower top line.

At the same time, LPKF announced an efficiency programme ("North Star", led by new CFO Peter Mümmler), which aims to increase internal efficiency and profitability and the company's resilience to top-line volatility. After already implementing cost-cutting measures in 2024, LPKF's new programme is likely to focus on the variabilisation of fixed costs e.g. via shared or outsourced R&D or non-core processes. LPKF has not issued details yet. The main target is to achieve a 10% EBIT margin on sales of EUR 125-130m, which would facilitate margins in the higher teens if sales are stronger. While some low hanging fruit might become effective as early as next year, most measures are expected to strengthen profitability from 2027 onwards.

The company's LIDE technology is expected to remain the most important future growth driver with the adoption in displays and advanced semiconductor packaging and the possibility to scale to a low triple-digit revenue contribution (up from EUR 10-15m currently) in the midterm.

The expectation of a return to stronger growth in 2026 remains largely unchanged for now as US tariff-related uncertainties should ease in the quarters to come and with the larger (LIDE, solar) projects in the pipeline. However, the forecasts are not yet backed by an existing order backlog.

The rating is being maintained with a PT of EUR 10 against the background of the mid-term growth and margin potential, which is largely based on the adoption of LIDE in display and/or semiconductor applications. However, visibility on the exact timing of the adoption remains low.

Changes in Estimates:

FY End: 31.12. in EUR m	2025e (old)	+ / -	2026e (old)	+ / -	2027e (old)	+ / -
Sales	128.0	-7.4 %	148.6	-5.8 %	172.0	-7.0 %
EBIT adj.	7.8	-82.8 %	14.6	-23.4 %	22.8	-7.4 %
EBIT	5.5	n.m.	14.6	-44.0 %	22.8	-7.4 %

Comment on Changes:

- Actual 2025/26 earnings figures include transformation-related costs
- Without larger LIDE orders, next year's sales would still remain at lower levels.
- Adj. EBIT margins should benefit from efficiency programme



Rel. Performance vs CDAX:	
1 month:	-10.5 %
6 months:	-13.9 %
Year to date:	-35.5 %
Trailing 12 months:	-39.7 %

Company events:	
30.10.25	Q3

FY End: 31.12. in EUR m	CAGR (24-27e)	2021	2022	2023	2024	2025e	2026e	2027e
Sales	9.2 %	93.6	123.7	124.3	122.9	118.5	140.0	160.1
Change Sales yoy		-2.8 %	32.2 %	0.5 %	-1.2 %	-3.5 %	18.1 %	14.4 %
Gross profit margin		*74.7 %*	*70.1 %*	*70.3 %*	*69.7 %*	*71.1 %*	*70.2 %*	*68.5 %*
EBITDA	73.7 %	7.6	15.1	12.8	5.8	7.0	17.3	30.6
Margin		*8.1 %*	*12.2 %*	*10.3 %*	*4.7 %*	*5.9 %*	*12.4 %*	*19.1 %*
EBIT		0.1	6.5	3.7	-2.5	-1.7	8.2	21.1
EBIT adj.	618.2 %	0.1	6.5	4.4	0.1	1.3	11.2	21.1
Margin		*0.1 %*	*5.3 %*	*3.5 %*	*0.0 %*	*1.1 %*	*8.0 %*	*13.2 %*
Net income	-	-0.1	1.4	1.8	-4.5	-2.3	4.8	14.0
EPS	-	0.00	0.06	0.07	-0.18	-0.09	0.19	0.57
EPS adj.	-	0.00	0.06	0.07	-0.18	-0.09	0.19	0.57
DPS	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCFPS		-0.03	0.01	-0.45	0.08	0.10	0.13	0.61
FCF / Market cap		-0.1 %	0.1 %	-4.9 %	0.9 %	1.5 %	1.9 %	8.8 %
EV / Sales		5.9 x	2.2 x	1.8 x	1.7 x	1.4 x	1.2 x	1.0 x
EV / EBITDA		72.1 x	17.9 x	17.8 x	36.6 x	24.5 x	9.7 x	5.0 x
EV / EBIT		n.a.	41.5 x	61.8 x	n.a.	n.a.	20.6 x	7.3 x
P / E		n.a.	190.2 x	131.1 x	n.a.	n.a.	36.6 x	12.2 x
FCF Potential Yield		1.1 %	2.9 %	3.9 %	1.4 %	3.2 %	7.5 %	14.1 %
Net Debt		-9.6	-9.0	3.3	3.5	0.9	-2.3	-17.3
ROCE (NOPAT)		0.0 %	1.8 %	2.3 %	n.a.	n.a.	6.4 %	16.1 %
Guidance:	Sales EUR 115-125m. Adj. EBIT margin 0-5%							

Analyst

Robert-Jan van der Horst

rvanderhorst@warburg-research.com

+49 40 309537-290

Sales development
in EUR m

Source: Warburg Research

Sales by regions
2024; in %



Source: Warburg Research

EBIT development
in EUR m



Source: Warburg Research

Company Background

- Global market leader/top supplier of laser-based processing tools replacing conventional and non-digital processes.
- LPKF is an innovation leader and usually the first supplier of new laser-based processing technologies.
- Approx. 50% of revenues are generated with the development and production of PCBs (segments Development and Electronics) where LPKF is global market leader with market shares of up to 65% in its applications.
- LPKF's Solar BU offers laser scriber to producers of thin film solar modules. In the future the new LTP technology will also contribute to this segment.
- The Welding segment offers versatile applications for a range of customer industries including automotive, consumer electronics and healthcare

Competitive Quality

- LPKF is the technologically leading company in the market of laser applications and often first supplier of its customers.
- The high innovative strength of the company ensures the market-leading position and gives LPKF a first-mover advantage in new products that offer highly attractive TCO compared to conventional solutions.
- The company holds a dominant market-leading position in selected niches (e.g. in development and solar segment) but there is also some dependency on single customers.
- International service and distribution network fosters close relationships to customers.
- The focused low-asset business model and high R&D efforts offer high scalability and attractive capital returns.

EBT development
in EUR m



Source: Warburg Research

Sales by segments
2024; in %



Source: Warburg Research

Net income development
in EUR m



Source: Warburg Research

DCF model

	Detailed forecast period			Transitional period										Term. Value
Figures in EUR m	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	2037e	
Sales	118.5	140.0	160.1	184.1	211.7	231.8	250.3	267.9	283.9	295.3	305.6	314.8	322.7	
Sales change	*-3.5 %*	*18.1 %*	*14.4 %*	*15.0 %*	*15.0 %*	*9.5 %*	*8.0 %*	*7.0 %*	*6.0 %*	*4.0 %*	*3.5 %*	*3.0 %*	*2.5 %*	*2.5 %*
EBIT	-1.7	8.2	21.1	24.1	27.3	29.4	31.8	34.0	36.1	37.5	38.8	39.4	40.3	
EBIT-margin	*-1.4 %*	*5.8 %*	*13.2 %*	*13.1 %*	*12.9 %*	*12.7 %*	*12.7 %*	*12.7 %*	*12.7 %*	*12.7 %*	*12.7 %*	*12.5 %*	*12.5 %*	
Tax rate (EBT)	*29.0 %*	*29.0 %*	*29.0 %*	*30.0 %*	*30.0 %*	*30.0 %*	*30.0 %*	*30.0 %*	*30.0 %*	*30.0 %*	*30.0 %*	*30.0 %*	*30.0 %*	
NOPAT	-1.2	5.8	15.0	16.9	19.1	20.6	22.3	23.8	25.2	26.3	27.2	27.5	28.2	
Depreciation	8.7	9.1	9.5	9.2	9.9	10.4	10.5	11.3	11.9	12.4	12.8	13.2	13.6	
in % of Sales	*7.3 %*	*6.5 %*	*5.9 %*	*5.0 %*	*4.7 %*	*4.5 %*	*4.2 %*	*4.2 %*	*4.2 %*	*4.2 %*	*4.2 %*	*4.2 %*	*4.2 %*	
Changes in provisions	0.0	0.0	0.0	-0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Change in Liquidity from														
- Working Capital	-4.1	3.3	3.4	6.2	6.9	5.0	4.6	4.4	4.0	2.8	2.6	2.3	2.0	
- Capex	8.1	8.7	8.6	9.2	9.5	9.7	10.0	10.7	11.4	11.8	12.2	12.6	12.9	
Capex in % of Sales	*6.8 %*	*6.2 %*	*5.4 %*	*5.0 %*	*4.5 %*	*4.2 %*	*4.0 %*	*4.0 %*	*4.0 %*	*4.0 %*	*4.0 %*	*4.0 %*	*4.0 %*	
- Other	0.6	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	2.9	2.3	11.9	10.2	12.6	16.3	18.1	20.0	21.8	24.0	25.2	25.9	26.9	28
PV of FCF	3.0	2.2	10.2	7.9	9.0	10.6	10.7	10.8	10.8	10.8	10.4	9.7	9.2	133
share of PVs	**6.16 %**			**40.18 %**										**53.65 %**

Model parameter

Derivation of WACC:		Derivation of Beta:	
Debt ratio	3.00 %	Financial Strength	1.10
Cost of debt (after tax)	2.8 %	Liquidity (share)	1.30
Market return	8.25 %	Cyclicality	1.30
Risk free rate	2.75 %	Transparency	1.40
		Others	1.30
WACC	**9.58 %**	**Beta**	**1.28**

Valuation (m)

Present values 2037e	115		
Terminal Value	133		
Financial liabilities	8		
Pension liabilities	0		
Hybrid capital	0		
Minority interest	0		
Market val. of investments	0		
Liquidity	5	No. of shares (m)	24.5
Equity Value	**245**	**Value per share (EUR)**	**10.01**

Sensitivity Value per Share (EUR)

		Terminal Growth						
Beta	WACC	1.75 %	2.00 %	2.25 %	**2.50 %**	2.75 %	3.00 %	3.25 %
1.47	10.6 %	8.23	8.34	8.46	8.59	8.73	8.87	9.03
1.37	10.1 %	8.82	8.96	9.10	9.25	9.42	9.60	9.78
1.33	9.8 %	9.15	9.29	9.45	9.62	9.80	10.00	10.21
1.28	9.6 %	9.49	9.66	9.83	**10.01**	10.21	10.43	10.66
1.23	9.3 %	9.86	10.04	10.23	10.44	10.66	10.90	11.15
1.19	9.1 %	10.26	10.46	10.67	10.89	11.14	11.40	11.69
1.09	8.6 %	11.14	11.38	11.64	11.92	12.22	12.55	12.91

		Delta EBIT-margin						
Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	**+0.0 pp**	+0.5 pp	+1.0 pp	+1.5 pp
1.47	10.6 %	7.33	7.75	8.17	8.59	9.01	9.43	9.85
1.37	10.1 %	7.91	8.36	8.81	9.25	9.70	10.15	10.60
1.33	9.8 %	8.23	8.69	9.16	9.62	10.08	10.55	11.01
1.28	9.6 %	8.57	9.05	9.53	**10.01**	10.49	10.98	11.46
1.23	9.3 %	8.94	9.44	9.94	10.44	10.94	11.43	11.93
1.19	9.1 %	9.34	9.86	10.38	10.89	11.41	11.93	12.45
1.09	8.6 %	10.24	10.80	11.36	11.92	12.48	13.04	13.60

- Comparably high growth rates in 2026 and 2027 driven by anticipated LIDE orders
- Margin increase resulting from the high scalability of LPKF's business model
- The "Others" line comprises adjustments for leasing related depreciations

Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

in EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Net Income before minorities	-0.1	1.4	1.8	-4.5	-2.3	4.8	14.0
+ Depreciation + Amortisation	7.5	8.6	9.1	8.4	8.7	9.1	9.5
- Net Interest Income	-0.2	-0.4	-0.6	-1.5	-1.5	-1.4	-1.4
- Maintenance Capex	1.9	2.5	2.5	2.5	2.4	2.8	3.2
+ Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Free Cash Flow Potential	**5.8**	**7.9**	**9.0**	**2.9**	**5.5**	**12.6**	**21.6**
FCF Potential Yield (on market EV)	1.1 %	2.9 %	3.9 %	1.4 %	3.2 %	7.5 %	14.1 %
WACC	9.58 %	9.58 %	9.58 %	9.58 %	9.58 %	9.58 %	9.58 %
= Enterprise Value (EV)	**547.8**	**270.6**	**228.1**	**213.2**	**171.4**	**168.2**	**153.2**
= Fair Enterprise Value	**60.3**	**82.3**	**93.8**	**30.6**	**57.9**	**131.0**	**225.9**
- Net Debt (Cash)	3.0	3.0	3.0	3.0	0.4	-2.7	-17.8
- Pension Liabilities	0.5	0.5	0.5	0.5	0.5	0.5	0.5
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
- Market value of minorities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Market value of investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Fair Market Capitalisation	**56.9**	**78.8**	**90.4**	**27.1**	**57.0**	**133.3**	**243.2**
Number of shares, average	24.5	24.5	24.5	24.5	24.5	24.5	24.5
= Fair value per share (EUR)	**2.32**	**3.22**	**3.69**	**1.11**	**2.33**	**5.44**	**9.93**
premium (-) / discount (+) in %					-66.6 %	-21.8 %	42.7 %

Sensitivity Fair value per Share (EUR)

		2021	2022	2023	2024	2025e	2026e	2027e
	12.58 %	1.73	2.42	2.78	0.81	1.76	4.17	7.73
	11.58 %	1.90	2.64	3.03	0.89	1.92	4.52	8.34
	10.58 %	2.09	2.90	3.33	0.99	2.10	4.94	9.06
WACC	**9.58 %**	**2.32**	**3.22**	**3.69**	**1.11**	**2.33**	**5.44**	**9.93**
	8.58 %	2.61	3.61	4.14	1.25	2.60	6.06	11.00
	7.58 %	2.97	4.10	4.70	1.44	2.95	6.85	12.36
	6.58 %	3.44	4.75	5.44	1.68	3.40	7.88	14.13

- To maintain its production, we assume an investment of 2% of sales

Valuation

	2021	2022	2023	2024	2025e	2026e	2027e
Price / Book	6.0 x	3.0 x	2.4 x	2.3 x	1.9 x	1.8 x	1.5 x
Book value per share ex intangibles	2.99	2.99	2.98	2.81	2.65	2.85	3.55
EV / Sales	5.9 x	2.2 x	1.8 x	1.7 x	1.4 x	1.2 x	1.0 x
EV / EBITDA	72.1 x	17.9 x	17.8 x	36.6 x	24.5 x	9.7 x	5.0 x
EV / EBIT	n.a.	41.5 x	61.8 x	n.a.	n.a.	20.6 x	7.3 x
EV / EBIT adj.*	n.a.	41.5 x	51.9 x	n.a.	127.3 x	15.1 x	7.3 x
P / FCF	n.a.	n.a.	n.a.	111.6 x	67.3 x	53.5 x	11.3 x
P / E	n.a.	190.2 x	131.1 x	n.a.	n.a.	36.6 x	12.2 x
P / E adj.*	n.a.	190.2 x	131.1 x	n.a.	n.a.	36.6 x	12.2 x
Dividend Yield	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCF Potential Yield (on market EV)	1.1 %	2.9 %	3.9 %	1.4 %	3.2 %	7.5 %	14.1 %

*Adjustments made for: -

Consolidated profit & loss

In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Sales	**93.6**	**123.7**	**124.3**	**122.9**	**118.5**	**140.0**	**160.1**
Change Sales yoy	-2.8 %	32.2 %	0.5 %	-1.2 %	-3.5 %	18.1 %	14.4 %
Increase / decrease in inventory	7.3	-5.2	1.5	-0.7	-1.3	0.3	0.3
Own work capitalised	5.9	6.3	5.3	5.7	5.6	5.6	5.3
Total Sales	**106.7**	**124.8**	**131.2**	**127.9**	**122.8**	**145.9**	**165.7**
Material expenses	36.8	38.0	43.7	42.2	38.5	47.6	56.0
Gross profit	**69.9**	**86.7**	**87.5**	**85.7**	**84.3**	**98.3**	**109.6**
Gross profit margin	*74.7 %*	*70.1 %*	*70.3 %*	*69.7 %*	*71.1 %*	*70.2 %*	*68.5 %*
Personnel expenses	44.3	49.5	52.4	57.0	56.9	59.0	55.9
Other operating income	3.3	4.2	4.2	4.6	4.1	3.9	4.0
Other operating expenses	21.2	26.4	26.5	27.4	24.5	25.9	27.2
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	**7.6**	**15.1**	**12.8**	**5.8**	**7.0**	**17.3**	**30.6**
Margin	*8.1 %*	*12.2 %*	*10.3 %*	*4.7 %*	*5.9 %*	*12.4 %*	*19.1 %*
Depreciation of fixed assets	3.8	4.1	4.6	4.4	4.3	4.2	4.0
EBITA	**3.8**	**11.0**	**8.2**	**1.4**	**2.7**	**13.1**	**26.6**
Amortisation of intangible assets	3.7	4.5	4.5	3.9	4.3	5.0	5.5
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	**0.1**	**6.5**	**3.7**	**-2.5**	**-1.7**	**8.2**	**21.1**
Margin	*0.1 %*	*5.3 %*	*3.0 %*	*-2.1 %*	*-1.4 %*	*5.8 %*	*13.2 %*
EBIT adj.	**0.1**	**6.5**	**4.4**	**0.1**	**1.3**	**11.2**	**21.1**
Interest income	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest expenses	0.2	0.4	0.6	1.5	1.5	1.4	1.4
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	**-0.2**	**6.1**	**3.1**	**-4.1**	**-3.2**	**6.7**	**19.7**
Margin	*-0.2 %*	*5.0 %*	*2.5 %*	*-3.3 %*	*-2.7 %*	*4.8 %*	*12.3 %*
Total taxes	-0.1	4.8	1.3	0.4	-0.9	1.9	5.7
Net income from continuing operations	**-0.1**	**1.4**	**1.8**	**-4.5**	**-2.3**	**4.8**	**14.0**
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	**-0.1**	**1.4**	**1.8**	**-4.5**	**-2.3**	**4.8**	**14.0**
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	**-0.1**	**1.4**	**1.8**	**-4.5**	**-2.3**	**4.8**	**14.0**
Margin	*-0.1 %*	*1.1 %*	*1.4 %*	*-3.7 %*	*-1.9 %*	*3.4 %*	*8.8 %*
Number of shares, average	24.5	24.5	24.5	24.5	24.5	24.5	24.5
EPS	**0.00**	**0.06**	**0.07**	**-0.18**	**-0.09**	**0.19**	**0.57**
EPS adj.	0.00	0.06	0.07	-0.18	-0.09	0.19	0.57

*Adjustments made for:

Guidance: Sales EUR 115-125m. Adj. EBIT margin 0-5%

Financial Ratios

	2021	2022	2023	2024	2025e	2026e	2027e
Total Operating Costs / Sales	105.9 %	88.7 %	95.2 %	99.3 %	97.7 %	91.8 %	84.4 %
Operating Leverage	35.8 x	339.8 x	-84.0 x	n.a.	9.9 x	n.a.	11.1 x
EBITDA / Interest expenses	30.8 x	37.9 x	20.7 x	3.8 x	4.6 x	12.0 x	22.4 x
Tax rate (EBT)	32.9 %	77.4 %	43.1 %	-10.8 %	29.0 %	29.0 %	29.0 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Sales per Employee	125,426	167,161	163,386	161,485	163,979	196,106	248,647

Sales, EBITDA
in EUR m



Source: Warburg Research

Operating Performance
in %



Source: Warburg Research

Performance per Share



Source: Warburg Research

Consolidated balance sheet

In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Assets							
Goodwill and other intangible assets	19.1	20.7	22.0	22.9	24.1	24.8	24.5
thereof other intangible assets	0.7	1.0	1.6	1.3	1.3	1.3	1.3
thereof Goodwill	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Property, plant and equipment	46.3	45.0	43.0	42.1	39.8	38.0	36.9
Financial assets	0.0	0.4	0.3	0.1	0.1	0.1	0.1
Other long-term assets	0.2	0.0	0.0	0.2	0.2	0.2	0.2
Fixed assets	**65.6**	**66.1**	**65.4**	**65.4**	**64.3**	**63.1**	**61.8**
Inventories	28.5	27.7	31.3	26.9	29.6	32.6	35.6
Accounts receivable	17.2	27.5	36.4	30.1	25.3	28.0	30.7
Liquid assets	15.2	12.8	10.7	5.1	7.6	10.8	25.8
Other short-term assets	5.8	4.4	4.7	4.2	4.2	4.2	4.2
Current assets	**66.7**	**72.3**	**83.0**	**66.2**	**66.7**	**75.6**	**96.3**
Total Assets	**132.2**	**138.4**	**148.5**	**131.6**	**130.9**	**138.7**	**158.1**
Liabilities and shareholders' equity							
Subscribed capital	24.5	24.5	24.5	24.5	24.5	24.5	24.5
Capital reserve	15.5	15.5	15.5	15.5	15.5	15.5	15.5
Retained earnings	12.0	12.7	12.2	13.3	11.0	15.8	29.8
Other equity components	40.2	41.2	43.0	38.5	38.1	38.7	41.8
Shareholders' equity	92.2	93.9	95.1	91.8	89.1	94.5	111.6
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	**92.2**	**93.9**	**95.1**	**91.8**	**89.1**	**94.5**	**111.6**
Provisions	2.7	3.9	3.6	4.3	4.3	4.3	4.3
thereof provisions for pensions and similar obligations	0.4	0.4	0.3	0.5	0.5	0.5	0.5
Financial liabilities (total)	5.2	3.4	13.6	8.0	8.0	8.0	8.0
Short-term financial liabilities	1.8	1.7	12.2	7.1	7.1	7.1	7.1
Accounts payable	7.2	7.5	10.0	7.4	7.8	9.2	10.5
Other liabilities	24.9	29.7	26.2	20.2	21.7	22.7	23.7
Liabilities	**40.0**	**44.5**	**53.4**	**39.8**	**41.8**	**44.2**	**46.5**
Total liabilities and shareholders' equity	**132.2**	**138.4**	**148.5**	**131.6**	**130.9**	**138.7**	**158.1**

Financial Ratios

	2021	2022	2023	2024	2025e	2026e	2027e
Efficiency of Capital Employment							
Operating Assets Turnover	1.4 x	1.7 x	1.5 x	1.5 x	1.6 x	1.9 x	2.1 x
Capital Employed Turnover	1.1 x	1.5 x	1.3 x	1.3 x	1.3 x	1.5 x	1.7 x
ROA	-0.2 %	2.1 %	2.7 %	-6.9 %	-3.5 %	7.5 %	22.7 %
Return on Capital							
ROCE (NOPAT)	0.0 %	1.8 %	2.3 %	n.a.	n.a.	6.4 %	16.1 %
ROE	-0.1 %	1.5 %	1.9 %	-4.8 %	-2.5 %	5.2 %	13.6 %
Adj. ROE	-0.1 %	1.5 %	1.9 %	-4.8 %	-2.5 %	5.2 %	13.6 %
Balance sheet quality							
Net Debt	-9.6	-9.0	3.3	3.5	0.9	-2.3	-17.3
Net Financial Debt	-10.0	-9.3	2.9	3.0	0.4	-2.7	-17.8
Net Gearing	-10.4 %	-9.6 %	3.4 %	3.8 %	1.0 %	-2.4 %	-15.5 %
Net Fin. Debt / EBITDA	n.a.	n.a.	22.9 %	51.1 %	6.3 %	n.a.	n.a.
Book Value / Share	3.8	3.8	3.9	3.7	3.6	3.9	4.6
Book value per share ex intangibles	3.0	3.0	3.0	2.8	2.7	2.8	3.6

ROCE Development



Source: Warburg Research

Net debt
in EUR m



Source: Warburg Research

Book Value per Share
in EUR



Source: Warburg Research

Consolidated cash flow statement

In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Net income	-0.1	1.4	1.8	-4.5	-2.3	4.8	14.0
Depreciation of fixed assets	3.8	4.1	4.6	4.4	4.3	4.2	4.0
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	3.7	4.5	4.5	3.9	4.3	5.0	5.5
Increase/decrease in long-term provisions	-0.5	1.1	-0.1	0.7	0.0	0.0	0.0
Other non-cash income and expenses	-0.8	6.3	1.8	-3.0	0.1	1.3	3.6
Cash Flow before NWC change	**6.1**	**17.4**	**12.5**	**1.6**	**6.5**	**15.2**	**27.0**
Increase / decrease in inventory	-9.4	-0.3	-5.0	3.8	-2.7	-3.0	-3.0
Increase / decrease in accounts receivable	-3.6	-10.3	-9.3	6.5	4.8	-2.7	-2.7
Increase / decrease in accounts payable	-0.5	0.3	2.3	-2.4	2.0	2.4	2.3
Increase / decrease in other working capital positions	15.3	1.5	-3.8	0.0	0.0	0.0	0.0
Increase / decrease in working capital (total)	1.8	-8.9	-15.9	7.9	4.1	-3.3	-3.4
Net cash provided by operating activities [1]	**7.9**	**8.5**	**-3.4**	**9.4**	**10.6**	**11.9**	**23.6**
Investments in intangible assets	-5.4	-6.2	-5.9	-4.8	-6.1	-6.3	-5.8
Investments in property, plant and equipment	-3.2	-2.1	-1.8	-2.8	-2.0	-2.4	-2.8
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.1	0.1	0.0	0.1	0.0	0.0	0.0
Net cash provided by investing activities [2]	**-8.6**	**-8.2**	**-7.7**	**-7.5**	**-8.1**	**-8.7**	**-8.6**
Change in financial liabilities	-2.1	-2.3	9.7	-13.0	0.0	0.0	0.0
Dividends paid	-2.5	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	-0.7	-0.8	-1.0	-1.0	0.0	0.0	0.0
Net cash provided by financing activities [3]	**-5.2**	**-3.1**	**8.7**	**-14.0**	**0.0**	**0.0**	**0.0**
Change in liquid funds [1]+[2]+[3]	**-5.9**	**-2.9**	**-2.4**	**-12.1**	**2.5**	**3.2**	**15.1**
Effects of exchange-rate changes on cash	1.0	0.5	0.3	0.2	0.0	0.0	0.0
Cash and cash equivalent at end of period	15.2	12.8	10.7	-1.2	7.6	10.8	25.8

Financial Ratios

	2021	2022	2023	2024	2025e	2026e	2027e
Cash Flow							
FCF	-0.8	0.2	-11.1	1.9	2.5	3.2	15.1
Free Cash Flow / Sales	-0.8 %	0.2 %	-8.9 %	1.5 %	2.1 %	2.3 %	9.4 %
Free Cash Flow Potential	5.8	7.9	9.0	2.9	5.5	12.6	21.6
Free Cash Flow / Net Profit	670.2 %	14.5 %	-631.1 %	-41.7 %	-112.3 %	67.0 %	107.3 %
Interest Received / Avg. Cash	0.1 %	0.2 %	0.1 %	0.0 %	0.0 %	0.0 %	0.0 %
Interest Paid / Avg. Debt	4.1 %	9.2 %	7.3 %	14.1 %	19.0 %	18.0 %	17.0 %
Management of Funds							
Investment ratio	9.3 %	6.7 %	6.2 %	6.1 %	6.8 %	6.2 %	5.4 %
Maint. Capex / Sales	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %
Capex / Dep	115.2 %	96.5 %	84.5 %	90.2 %	93.3 %	95.1 %	90.7 %
Avg. Working Capital / Sales	21.2 %	18.3 %	26.5 %	31.4 %	29.7 %	24.8 %	23.8 %
Trade Debtors / Trade Creditors	238.2 %	365.8 %	365.3 %	409.0 %	324.4 %	304.3 %	292.4 %
Inventory Turnover	1.3 x	1.4 x	1.4 x	1.6 x	1.3 x	1.5 x	1.6 x
Receivables collection period (days)	67	81	107	89	78	73	70
Payables payment period (days)	71	72	83	64	74	71	68
Cash conversion cycle (Days)	88	68	137	151	152	137	129

CAPEX and Cash Flow

in EUR m



Source: Warburg Research

Free Cash Flow Generation



Source: Warburg Research

Working Capital

Source: Warburg Research

LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All **data and consensus estimates** have been obtained from FactSet except where stated otherwise.

Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.

3. CIC (Crédit Industriel et Commercial) and M.M.Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.

4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.

5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

-1-	Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
-2-	Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
-3-	Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
-4-	MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of confidential business information.
-5-	The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
-6a-	Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
-6b-	Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
-6c-	The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
-7-	The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
LPKF	5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE0006450000.htm

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given price target in the opinion of the analyst who covers this financial instrument.

-B-	**Buy:**	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	**Hold:**	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	**Sell:**	The price of the analysed financial instrument is expected to fall over the next 12 months.
"-"	**Rating suspended:**	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	142	71
Hold	46	23
Sell	7	4
Rating suspended	4	2
Total	**199**	**100**

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING …

… taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	39	76
Hold	9	18
Sell	1	2
Rating suspended	2	4
Total	**51**	**100**

PRICE AND RATING HISTORY LPKF AS OF 17.09.2025



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

EQUITIES

Matthias Rode Head of Equities	+49 40 3282-2678 mrode@mmwarburg.com

RESEARCH

Henner Rüschmeier Head of Research	+49 40 309537-270 hrueschmeier@warburg-research.com
Stefan Augustin Cap. Goods, Engineering	+49 40 309537-168 saugustin@warburg-research.com
Christian Cohrs Industrials & Transportation	+49 40 309537-175 ccohrs@warburg-research.com
Felix Ellmann Software, IT	+49 40 309537-120 fellmann@warburg-research.com
Jörg Philipp Frey Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com
Marius Fuhrberg Financial Services	+49 40 309537-185 mfuhrberg@warburg-research.com
Fabio Hölscher Automobiles, Car Suppliers	+49 40 309537-240 fhoelscher@warburg-research.com
Philipp Kaiser Real Estate, Construction	+49 40 309537-260 pkaiser@warburg-research.com
Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257 tkleibauer@warburg-research.com
Andreas Pläsier Banks, Financial Services	+49 40 309537-246 aplaesier@warburg-research.com
Malte Schaumann Technology	+49 40 309537-170 mschaumann@warburg-research.com
Oliver Schwarz Chemicals, Agriculture	+49 40 309537-250 oschwarz@warburg-research.com
Simon Stippig Real Estate, Telco	+49 40 309537-265 sstippig@warburg-research.com
Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
Robert-Jan van der Horst Technology	+49 40 309537-290 rvanderhorst@warburg-research.com

INSTITUTIONAL EQUITY SALES

Klaus Schilling Head of Equity Sales, Germany	+49 69 5050-7400 kschilling@mmwarburg.com
Tim Beckmann United Kingdom	+49 40 3282-2665 tbeckmann@mmwarburg.com
Jens Buchmüller Scandinavia, Austria	+49 69 5050-7415 jbuchmueller@mmwarburg.com
Matthias Fritsch United Kingdom, Ireland	+49 40 3282-2696 mfritsch@mmwarburg.com
Roman Alexander Niklas Switzerland, Poland, Italy	+49 69 5050-7412 rniklas@mmwarburg.com
Sascha Propp France	+49 40 3282-2656 spropp@mmwarburg.com
Leyan Ilkbahar Roadshow/Marketing	+49 40 3282-2695 lilkbahar@mmwarburg.com
Antonia Möller Roadshow/Marketing	+49 69 5050-7417 amoeller@mmwarburg.com
Juliane Niemann Roadshow/Marketing	+49 40 3282-2694 jniemann@mmwarburg.com

SALES TRADING

Oliver Merckel Head of Sales Trading	+49 40 3282-2634 omerckel@mmwarburg.com
Bastian Quast Sales Trading	+49 40 3282-2701 bquast@mmwarburg.com
Christian Salomon Sales Trading	+49 40 3282-2685 csalomon@mmwarburg.com

DESIGNATED SPONSORING

Sebastian Schulz Designated Sponsoring	+49 40 3282-2631 sschulz@mmwarburg.com
Jörg Treptow Designated Sponsoring	+49 40 3282-2658 jtreptow@mmwarburg.com

MACRO RESEARCH

Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com
Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com

Our research can be found under:

Warburg Research	research.mmwarburg.com/en/index.html
Bloomberg	RESP MMWA GO
FactSet	www.factset.com
LSEG	www.lseg.com
Capital IQ	www.capitaliq.com

For access please contact:

Andrea Schaper Sales Assistance	+49 40 3282-2632 aschaper@mmwarburg.com
Kerstin Muthig Sales Assistance	+49 40 3282-2703 kmuthig@mmwarburg.com